Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain)
- PMID: 23114195
- PMCID: PMC3532136
- DOI: 10.1186/1471-2334-12-283
Retrospective epidemiological study for the characterization of community- acquired pneumonia and pneumococcal pneumonia in adults in a well-defined area of Badalona (Barcelona, Spain)
Abstract
Background: Community-acquired pneumonia (CAP) has large impact on direct healthcare costs, especially those derived from hospitalization. This study determines impact, clinical characteristics, outcome and economic consequences of CAP in the adult (≥18 years) population attended in 6 primary-care centers and 2 hospitals in Badalona (Spain) over a two-year period.
Methods: Medical records were identified by codes from the International Classification of Diseases in databases (January 1st 2008-December 31st 2009).
Results: A total of 581 patients with CAP (55.6% males, mean age 57.5 years) were identified. Prevalence: 0.64% (95% CI: 0.5%-0.7%); annual incidence: 3.0 cases/1,000 inhabitants (95% CI: 0.2-0.5). Up to 241 (41.5%) required hospitalization. Hospital admission was associated (p<0.002) with liver disease (OR=5.9), stroke (OR=3.6), dementia (OR=3.5), COPD (OR=2.9), diabetes mellitus (OR=1.9) and age (OR=1.1 per year). Length of stay (4.4±0.3 days) was associated with PSI score (β=0.195), in turn associated with age (r=0.827) and Charlson index (r=0.497). Microbiological tests were performed in all inpatients but only in 35% outpatients. Among patients with microbiological tests, results were positive in 51.7%, and among them, S pneumoniae was identified in 57.5% cases. Time to recovery was 29.9±17.2 days. Up to 7.5% inpatients presented complications, 0.8% required ICU admission and 19.1% readmission. Inhospital mortality rate was 2.5%. Adjusted mean total cost was €2,332.4/inpatient and €698.6/outpatient (p<0.001). Patients with pneumococcal CAP (n=107) showed higher comorbidity and hospitalization (76.6%), higher PSI score, larger time to recovery and higher overall costs among inpatients.
Conclusions: Strategies preventing CAP, thus reducing hospital admissions could likely produce substantial costs savings in addition to the reduction of CAP burden.
Similar articles
-
Burden of pneumococcal pneumonia requiring ICU admission in France: 1-year prognosis, resources use, and costs.Crit Care. 2021 Jan 10;25(1):24. doi: 10.1186/s13054-020-03442-z. Crit Care. 2021. PMID: 33423691 Free PMC article.
-
Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis.Vaccine. 2015 Jun 22;33(28):3193-9. doi: 10.1016/j.vaccine.2015.05.001. Epub 2015 May 14. Vaccine. 2015. PMID: 25981488
-
Hospitalisation with community-acquired pneumonia among patients with type 2 diabetes: an observational population-based study in Spain from 2004 to 2013.BMJ Open. 2017 Jan 5;7(1):e013097. doi: 10.1136/bmjopen-2016-013097. BMJ Open. 2017. PMID: 28057653 Free PMC article.
-
Burden of community-acquired pneumonia in North American adults.Postgrad Med. 2010 Mar;122(2):130-41. doi: 10.3810/pgm.2010.03.2130. Postgrad Med. 2010. PMID: 20203464 Review.
-
Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.Respir Med. 2018 Apr;137:6-13. doi: 10.1016/j.rmed.2018.02.007. Epub 2018 Feb 19. Respir Med. 2018. PMID: 29605214 Review.
Cited by
-
Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease.Thorax. 2015 Oct;70(10):984-9. doi: 10.1136/thoraxjnl-2015-206780. Epub 2015 Jul 28. Thorax. 2015. PMID: 26219979 Free PMC article. Review.
-
Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults.Infection. 2015 Dec;43(6):699-706. doi: 10.1007/s15010-015-0801-y. Epub 2015 Jun 3. Infection. 2015. PMID: 26037386
-
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors.Hum Vaccin Immunother. 2023 Dec 31;19(1):2177066. doi: 10.1080/21645515.2023.2177066. Epub 2023 Mar 2. Hum Vaccin Immunother. 2023. PMID: 36864601 Free PMC article. Clinical Trial.
-
CAPPRIC Study-Characterization of Community-Acquired Pneumonia in Spanish Adults Managed in Primary Care Settings.Microorganisms. 2021 Feb 28;9(3):508. doi: 10.3390/microorganisms9030508. Microorganisms. 2021. PMID: 33670930 Free PMC article.
-
Validation for using electronic health records to identify community acquired pneumonia hospitalization among people with and without HIV.Pneumonia (Nathan). 2020 Jul 25;12:6. doi: 10.1186/s41479-020-00068-1. eCollection 2020. Pneumonia (Nathan). 2020. PMID: 32724760 Free PMC article.
References
-
- British Thoracic Society. Guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl. III):iii1–iii55. - PubMed
-
- de Miguel DJ, Alvarez-Sala JL. Prognostic factors in community-acquired pneumonia [Article in Spanish] An Med Interna. 2007;24:465–466. - PubMed
-
- Gutiérrez F, Masiá M, Rodríguez JC, Mirete C, Soldán B, Padilla S, Hernández I, De Ory F, Royo G, Hidalgo AM. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect. 2005;11:788–800. doi: 10.1111/j.1469-0691.2005.01226.x. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous